Literature DB >> 21431960

Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells.

Xu-Yuan Li1, Ying-Cheng Lin, Wan-Lan Huang, Chao-Qun Hong, Jiong-Yu Chen, Yan-Jie You, Wei-Bing Li.   

Abstract

To demonstrate the effect of zoledronic acid in proliferation, invasion, and migration of human nasopharyngeal carcinoma cell HNE-1 and explore the potential role of VEGF, MMP-2, and MMP-9 proteins in vitro. Human nasopharyngeal carcinoma cell HNE-1 was exposed to various concentrations (0-40 μmol/l) of zoledronic acid. Zoledronic acid inhibited proliferation of HNE-1 cells though not in a dose-dependent manner. Zoledronic acid had exerted a dose-dependent effect on the migration and invasion of HNE-1 cells. Both expressions of mRNA and protein of MMP2, MMP9, and VEGF were reduced, respectively, detected by RT-PCR and Western blot assays. These data suggested that zoledronic acid not only inhibited growth but also invasion and migration of HNE-1 cells in vitro. The anti-cancer action of zoledronic acid was partially associated with the suppression of VEGF expression and secretion and downregulating the expression of MMP2 and MMP9.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21431960     DOI: 10.1007/s12032-011-9904-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

Review 1.  Nasopharyngeal carcinoma: the next challenges.

Authors:  Albiruni R A Razak; Lillian L Siu; Fei-Fei Liu; Emma Ito; Brian O'Sullivan; Kelvin Chan
Journal:  Eur J Cancer       Date:  2010-05-05       Impact factor: 9.162

2.  Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Sara Galluzzo; Fabrizio Battistoni; Laura Rocci; Olga Venditti; Gaia Schiavon; Silvia Angeletti; Federica Uzzalli; Michele Caraglia; Giordano Dicuonzo; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

Review 3.  The aetiology of nasopharyngeal carcinoma.

Authors:  A L McDermott; S N Dutt; J C Watkinson
Journal:  Clin Otolaryngol Allied Sci       Date:  2001-04

4.  Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.

Authors:  Brigitte Rack; Julia Jückstock; Eva-Maria Genss; Alexandra Schoberth; Christian Schindlbeck; Barbara Strobl; Maja Heinrigs; Gerhard Rammel; Thomas Zwingers; Harald Sommer; Klaus Friese; Wolfgang Janni
Journal:  Anticancer Res       Date:  2010-05       Impact factor: 2.480

5.  Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.

Authors:  Gianluigi Ferretti; Alessandra Fabi; Paolo Carlini; Paola Papaldo; Paola Cordiali Fei; Serena Di Cosimo; Nello Salesi; Diana Giannarelli; Andrea Alimonti; Barbara Di Cocco; Giovanna D'Agosto; Valentina Bordignon; Elisabetta Trento; Francesco Cognetti
Journal:  Oncology       Date:  2005-08-02       Impact factor: 2.935

6.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Authors:  Rebecca Aft; Michael Naughton; Kathryn Trinkaus; Mark Watson; Lourdes Ylagan; Mariana Chavez-MacGregor; Jing Zhai; Sacha Kuo; William Shannon; Kathryn Diemer; Virginia Herrmann; Jill Dietz; Amjad Ali; Matthew Ellis; Peter Weiss; Timothy Eberlein; Cynthia Ma; Paula M Fracasso; Imran Zoberi; Marie Taylor; William Gillanders; Timothy Pluard; Joanne Mortimer; Katherine Weilbaecher
Journal:  Lancet Oncol       Date:  2010-03-31       Impact factor: 41.316

Review 7.  Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.

Authors:  Philippe Clézardin; Frank H Ebetino; Pierrick G J Fournier
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

8.  Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

Authors:  Penelope D Ottewell; Blandine Deux; Hannu Mönkkönen; Simon Cross; Robert E Coleman; Philippe Clezardin; Ingunn Holen
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

Review 9.  Zoledronic acid - a multiplicity of anti-cancer action.

Authors:  Takeshi Yuasa; Shinya Kimura; Eishi Ashihara; Tomonori Habuchi; Taira Maekawa
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

10.  Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.

Authors:  Francesco Fabbri; Giovanni Brigliadori; Silvia Carloni; Paola Ulivi; Ivan Vannini; Anna Tesei; Rosella Silvestrini; Dino Amadori; Wainer Zoli
Journal:  J Transl Med       Date:  2008-08-08       Impact factor: 5.531

View more
  15 in total

1.  Zoledronic acid inhibits human nasopharyngeal carcinoma cell proliferation by activating mitochondrial apoptotic pathway.

Authors:  Xu-Yuan Li; Ying-Cheng Lin; Wan-Lan Huang; Wen Lin; Hong-Biao Wang; Wen-Zhao Lin; Sui-Ling Lin
Journal:  Med Oncol       Date:  2012-06-23       Impact factor: 3.064

2.  Zoledronic acid augments the radiosensitivity of cancer cells through perturbing S- and M-phase cyclins and p21CIP1 expression.

Authors:  Chi Du; Yuyi Wang; Haijun Li; Yi Huang; Ou Jiang; Yanjie You; Feng Luo
Journal:  Oncol Lett       Date:  2017-08-03       Impact factor: 2.967

Review 3.  Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting.

Authors:  Nabil M Abdel-Hamid; Shimaa A Abass
Journal:  Mol Biol Rep       Date:  2021-08-11       Impact factor: 2.316

4.  High expression of Fibronectin 1 suppresses apoptosis through the NF-κB pathway and is associated with migration in nasopharyngeal carcinoma.

Authors:  Jinting Wang; Lian Deng; Junpeng Huang; Rui Cai; Xiongjie Zhu; Faquan Liu; Qien Wang; Jiren Zhang; Yanfang Zheng
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

5.  Association of Acroosteolysis With Enhanced Osteoclastogenesis and Higher Blood Levels of Vascular Endothelial Growth Factor in Systemic Sclerosis.

Authors:  Jin Kyun Park; Andrea Fava; John Carrino; Filippo Del Grande; Antony Rosen; Francesco Boin
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

Review 6.  The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities.

Authors:  Christiana M Neophytou; Myrofora Panagi; Triantafyllos Stylianopoulos; Panagiotis Papageorgis
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

Review 7.  Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma.

Authors:  Zhuo Chen; Xin-Hua Xu
Journal:  Saudi Med J       Date:  2015-06       Impact factor: 1.484

8.  Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

Authors:  Daniele Fanale; Valeria Amodeo; Viviana Bazan; Lavinia Insalaco; Lorena Incorvaia; Nadia Barraco; Marta Castiglia; Sergio Rizzo; Daniele Santini; Antonio Giordano; Sergio Castorina; Antonio Russo
Journal:  Oncotarget       Date:  2016-05-17

9.  CT-diagnosed severe skull base bone destruction predicts distant bone metastasis in early N-stage nasopharyngeal carcinoma.

Authors:  Wei Yi; Zhi-Gang Liu; Xian Li; Jiao Tang; Chang-Bin Jiang; Jing-Ye Hu; Zi-Wei Tu; Hui Wang; Dao-Li Niu; Yun-Fei Xia
Journal:  Onco Targets Ther       Date:  2016-11-14       Impact factor: 4.147

10.  Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion.

Authors:  Eva Rietkötter; Kerstin Menck; Annalen Bleckmann; Katja Farhat; Meike Schaffrinski; Matthias Schulz; Uwe-Karsten Hanisch; Claudia Binder; Tobias Pukrop
Journal:  Oncotarget       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.